Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Shanghai's SARI to Acquire NMS, an Italian Oncology Company, for $359 Million

publication date: Dec 28, 2017

Shanghai's SARI will pay $359 million to acquire a 90% interest in Group NMS, a Milan oncology biopharma. SARI is a biopharma investment firm affiliated with the Chinese Academy of Science research organization with the same name. SARI intends to bring NMS oncology drug candidates to China and integrate the features of the NMS development technology into its own. For the NMS transaction, SARI was the leading investor in a specific fund formed to acquire NMS. It was joined by Hicin Pharma, V-capital and FeiDong Investment. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here